ANI Pharmaceuticals Inc (ANIP)
Financial leverage ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total assets | US$ in thousands | 904,422 | 889,914 | 859,341 | 765,224 | 760,087 | 739,110 | 751,334 | 744,846 | 771,598 | 470,454 | 480,159 | 463,843 | 461,190 | 462,581 | 465,391 | 482,232 | 456,789 | 456,775 | 446,906 | 434,390 |
Total stockholders’ equity | US$ in thousands | 432,749 | 429,861 | 409,622 | 314,632 | 313,690 | 311,825 | 312,108 | 321,244 | 333,890 | 191,403 | 191,917 | 203,712 | 195,700 | 195,100 | 191,344 | 201,171 | 212,791 | 213,130 | 207,656 | 199,712 |
Financial leverage ratio | 2.09 | 2.07 | 2.10 | 2.43 | 2.42 | 2.37 | 2.41 | 2.32 | 2.31 | 2.46 | 2.50 | 2.28 | 2.36 | 2.37 | 2.43 | 2.40 | 2.15 | 2.14 | 2.15 | 2.18 |
December 31, 2023 calculation
Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $904,422K ÷ $432,749K
= 2.09
The financial leverage ratio of ANI Pharmaceuticals Inc has shown some fluctuations over the past 8 quarters. The ratio has ranged from a low of 1.96 in Q3 2023 to a high of 2.25 in both Q1 and Q4 of 2023. This indicates that the company relies more on debt financing rather than equity to fund its operations and investment activities.
A financial leverage ratio of above 1 suggests that the company has more debt than equity in its capital structure. ANI Pharmaceuticals Inc has maintained a consistently higher financial leverage ratio throughout the period, indicating a relatively aggressive capital structure.
It is important to monitor the trend of the financial leverage ratio over time as significant changes can impact the company's financial stability and risk profile. A higher leverage ratio can magnify returns to shareholders when the company is performing well, but it also increases the risk of financial distress during economic downturns. Investors and stakeholders should closely monitor ANI Pharmaceuticals Inc's leverage ratio and its impact on the company's overall financial health.
Peer comparison
Dec 31, 2023